Skip to main content

Table 4 Comparison between the present study and the previous studies of LAHCC

From: Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma

Reference Year n Treatment Method OS
Kudo M, et al. [3] 2018 250 Lenvatinib Median OS: 11.5 months
Bruix J, et al. [4] 2012 108 Sorafenib Median OS: 8.1 months
Yoon SM, et al. [5]) 2018 45 Sorafenib Median OS: 9.9 months
Kodama K, et al. [21] 2018 36 Sorafenib Median OS: 5.3 months
Kodama K, et al. [21] 2018 36 HAIC with RT Median OS: 9.9 months
Yoon SM, et al. [5] 2018 45 TACE with RT Median OS: 12.7 months
Zhang X, et al.a [22] 2017 21–604 Sorafenib Median OS: 7.0–13.0 months
Kudo M, et al. [15] 2019 1101 Surgery 3y-OS: 40%
Liu PH, et al. [23] 2014 247 Surgery 3y-OS: 68%
Shi J, et al. [24] 2010 406 Surgery 3y-OS: 13%
Komatsu S, et al. [25] 2017 19 Particle RT (proton beam therapy and C-ion RT) Median OS: 24.6 months
Present study   11 C-ion RT Median OS: 36.4 months, 3y-OS: 64%
  1. aReview article
  2. Abbreviations: C-ion RT carbon ion radiotherapy, HAIC hepatic arterial infusion chemotherapy, OS overall survival, RT radiotherapy, TACE transarterial chemoembolization, 3y-OS 3-year overall survival